PanGenomic Health Inc. (CSE: NARA) has announced a one-year exclusive distributorship agreement with Zeotech Group S.A.S., a Colombian subsidiary of US-based Ayla Bioscience Inc., granting PanGenomic Health the right to market and sell Zeotech's natural health product lines across Canada. Simultaneously, the company confirmed that its previously announced non-binding Letter of Intent to pursue a business combination with Ayla Bioscience has expired without a transaction. The dual announcement marks a strategic pivot from a proposed merger to a narrower commercial distribution relationship, which investors in the precision health space may be watching closely.
Key Points
- PanGenomic Health Inc. (CSE: NARA, FSE: LL3) is a Vancouver-based precision health and digital wellness company.
- The company signed an exclusive one-year distributorship agreement with Zeotech Group S.A.S. to market and sell natural health products in Canada.
- The non-binding Letter of Intent with Ayla Bioscience, first announced April 14, 2026, has now expired in accordance with its terms.
- Investors may watch how PanGenomic Health's Agenta ecommerce platform and retail partnerships perform in distributing Zeotech's product lines.
Zeotech Product Lines PanGenomic Health Will Distribute in Canada
Under the Distributorship Agreement, PanGenomic Health gains exclusive Canadian rights to market and sell three Zeotech product lines: Zeofoodz, described as high-nutrition functional foods; Zeophytoz, a line of botanical extracts and resins; and Zeomycel, a line of functional mushrooms. The release states that all products are made from natural ingredients sourced in the Andean and Amazon basins of South America. Zeotech's Bogota-based production facility uses patented dehydration technologies that the company says preserve molecular structure and biological activity of the natural inputs.
Agenta Ecommerce Platform and Retail Partners as Distribution Channels
PanGenomic Health plans to sell the Zeotech products as private-labelled offerings through its Agenta ecommerce platform and through natural health retail partners in Canada. The company did not disclose specific retail partner names, projected revenue targets, or volume commitments in the announcement. The one-year exclusivity window gives PanGenomic Health an initial period to establish market presence for the Zeotech range within Canada's natural health product sector before any renewal or renegotiation of exclusivity terms would need to be addressed.
Ayla Bioscience Merger Letter of Intent Expires Without a Deal
PanGenomic Health confirmed it is no longer pursuing the proposed business combination with Ayla Bioscience Inc. that was first announced on April 14, 2026. The non-binding Letter of Intent expired according to its own terms, and the company did not indicate any further merger or acquisition discussions with Ayla Bioscience. The release states PanGenomic Health will continue exploring partnership opportunities to build out a broader product suite supporting personalised medicine and natural health solutions, though no specific transactions or partnerships beyond the Zeotech agreement were disclosed. The immediate share price impact was not clear from available public information.




Please wait processing your request...